This article first appeared on GuruFocus .
Release Date: August 12, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Record Q2 2026 revenue of $909,000, up 61% sequentially and 115% year-over-year, with Q2 alone representing 83% of full-year 2025 revenue.
-
Active commercial cancer centers increased 31% to 21, with a robust pipeline of 42 additional centers, supporting the target of 36 by year-end 2026.
-
First commercial use of RenovoCath in sarcoma, demonstrating expansion beyond pancreatic cancer and physician-driven adoption.
-
Phase 3 TIGERPAC trial achieved full enrollment, with top-line data expected in the back half of 2027, a key value driver.
-
Strong gross margin of 84%, with management expecting further improvement from next-generation product, and a clear path to cash flow breakeven by Q4 2027.
Negative Points
-
Cash position declined to $9.5 million from $12.4 million in Q1, with a burn rate that, while declining, still requires careful management.
-
Operating loss remains significant at $3.4 million for the quarter, though improved from the prior quarter.
-
The company is still far from profitability, with breakeven not expected until late 2027, and requires continued revenue scaling.
-
Dependence on a small number of high-volume centers for a large portion of revenue, with many pipeline centers yet to convert to active users.
-
The TIGERPAC trial's success is not guaranteed, and a negative readout could impact adoption and reimbursement, though the company is not a binary event.
Q & A Highlights
Q: Now that enrollment for the TIGERPAC study is closed, how many of the patients actually ended up randomized? Did the number fall above or below the full 114 patients? A: Sean Bhagat (CEO): We haven't yet completed randomization; it's still in process. We didn't report the exact number publicly, but we are very close, with only a handful of patients left. We intentionally kept the study open a bit longer than anticipated to allow physicians to enroll patients and have them in the induction phase, creating a buffer to ensure we can randomize the 114 patients without issue if there are dropouts.
Q: What gives you confidence that you can reach the target of 36 active commercial centers by the end of the year, and how many of these are from clinical trial conversions? A: Sean Bhagat (CEO): The 21 active centers were as of the end of the quarter, and we've activated more since then. Our confidence comes from having 42 additional centers in the pipeline, which is well over the 36 target. The bulk of the 15 TIGERPAC sites have not yet begun treating commercially, as a handful wanted to wait until enrollment was complete to avoid competing interests. We anticipate activating those over the next quarter or two, which should contribute meaningfully to revenue, alongside the other 40-plus centers in the customer pipeline.
Q: On the clinical trial sites that become active commercial sites, what is the anticipated timeline from when they are activated to when they place their first order? A: Sean Bhagat (CEO): When we say "active," these are sites that have already purchased a catheter and treated a patient. We deliberately avoid counting sites that are merely ready to go or haven't purchased a device yet. The other 42 in the pipeline are at various stages, including being greenlit to order or having ordered but not yet treated their first patient. So, our definition of active is strictly purchasing and using customers.
Q: As you scale up volume for RenovoCath, do you think your gross margins and operating margins can go higher? A: Mark Fall (CFO): Yes, we have the opportunity to increase gross margins when we introduce our next-generation product, which we expect to launch sometime next year. That should allow us to improve from our current gross margin level of approximately 84%.
Q: Is there any difference in the volume or business potential of the additional centers in your pipeline compared to the first 21 you have already activated? Are they smaller or the same size? A: Sean Bhagat (CEO): The 21 active centers are a good representation of the full spectrum, including high-volume centers and smaller community-based hospitals. We haven't yet hit all the high-volume places, so there is significant opportunity for revenue growth. Mark Fall (CFO): The market is concentrated, with the top 10 advanced cancer centers representing about 25% of the market. While we target the larger ones, we are bringing a broad range of centers online, but securing the larger centers will provide the largest revenue opportunity.
Q: Can you provide additional color on what prompted the physician to use TAMP and RenovoCath in that particular sarcoma patient? A: Sean Bhagat (CEO): This was a physician who became comfortable treating pancreatic cancer with the technology and saw a case with a difficult-to-treat sarcoma tumor. He believed RenovoCath would be a great opportunity to isolate flow and achieve good tumor penetration of the drug. Interventional radiologists are inventive and work across the entire body; as many doctors have told us, once they have the device in their hands, they see opportunities to use it with other tumors and patients. This is the beginning of adoption across a spectrum of areas.
Q: How can learnings from activating the first set of commercial centers help facilitate the conversion of additional centers from your pipeline? A: Sean Bhagat (CEO): This is why we didn't hire a large sales force last yearto understand the sales cycle and process. We found there are many moving parts, including getting approvals to purchase the catheter and ensuring referring physicians know the technology is available. Key learnings to accelerate site activation include securing buy-in from multiple specialties, strong communication, and high-touch points. Having a small, dedicated field force showing up on-site is helping drive this, rather than pursuing a partnership at this early stage of market development.
Q: With the recent industry attention on new pancreatic cancer therapies, how do you view these developments impacting RenovoRx's opportunity? A: Sean Bhagat (CEO): We see breakthroughs in pancreatic cancer therapy as complementary and a tailwind for our business. RenovoCath is a device to deliver treatments more optimally, and our TAMP technology is a localized drug delivery platform. We can deliver established drugs locally alongside novel therapies, and as new drugs come to market, many can be delivered directly via RenovoCath. In both cases, novel improved therapies make our targeted delivery platform even more valuable.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
